NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

• Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA^® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients
• NGM831 is the second of three programs comprising NGM Bio’s wholly-owned myeloid reprogramming and checkpoint inhibition portfolio to enter the clinic
• NGM831, NGM707 and NGM438 are engineered to release myeloid checkpoints and reprogram myeloid cells to enhance anti-tumor immunity
• NGM Bio is currently enrolling patients in a Phase 1/2 trial of NGM707 and plans to initiate first-in-human trial of NGM438 in the second quarter of 2022

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has dosed the first patient in a Phase 1/1b clinical trial of NGM831 for the treatment of patients with advanced solid tumors. NGM831 is an antagonist antibody product candidate designed to block the interaction of ILT3 (also known as LILRB4) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. ILT3 is one of several receptors belonging to the LILR family that may play a central role in establishing an immune suppressive state in the tumor microenvironment. NGM831 is the second of three programs in NGM Bio’s wholly-owned myeloid reprogramming and checkpoint inhibition portfolio to enter the clinic. All three programs in the portfolio, which also includes NGM707 and NGM438, are engineered to target various LILR suppressive receptors with the goal of releasing myeloid checkpoints and reprogramming myeloid cells to enhance anti-tumor immunity.

“We are proud to be among the leaders in developing an emerging class of molecules designed to inhibit myeloid checkpoints of the anti-tumor immune response. We believe this new, exciting frontier in checkpoint inhibition has the potential to enable the more effective treatment of multiple cancers, many of which elude current checkpoint inhibition approaches,” said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM Bio. “NGM831’s entry into the clinic is another important milestone in our myeloid and stromal checkpoint development strategy. By mid-2022, we expect all three programs, which are directed at multiple and distinct targets, to be in the clinic.”

NGM707, a dual ILT2/ILT4 antagonist antibody, is currently enrolling patients in an ongoing Phase 1/2 trial for the treatment of patients with advanced solid tumors and is expected to enroll approximately 180 patients. NGM438, a LAIR1 antagonist antibody, is anticipated to enter the clinic in the second quarter of 2022. NGM Bio plans to implement a robust biomarker strategy across the NGM707, NGM831 and NGM438 clinical development programs to help inform target patient populations for each product candidate.

Click the button below to read the entire Press Release:

Continue Reading The Press Release